Prevalence of Presbyopia (Near Vision Fatigue) and Related Factors Among Working Adults Aged 30 to 55 Years in Shanghai
NCT07924475, Not yet recruiting, Shanghai Eye Disease Prevention and Treatment Center
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Prevalence of Presbyopia (Near Vision Fatigue) and Related Factors Among Working Adults Aged 30 to 55 Years in Shanghai | ClinicalTrials.gov |
| NCT number | NCT07924475 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 1,366 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Shanghai Eye Disease Prevention and Treatment Center | ClinicalTrials.gov |
| Conditions | Presbyopia | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Prevalence of presbyopia among working adults aged 30 to 55 years in Shanghai | Day 1 (At the single study visit (cross-sectional assessment)) | Proportion of participants meeting the study definition of presbyopia: binocular near visual acuity worse than N8 (equivalent to 20/50) at 40 cm under standard illumination with full distance refractive correction, improving by at least one line to N8 or better after binocular addition of plus lenses, after exclusion of organic ocular disease that could independently explain reduced near vision. Reported as a percentage with 95 percent confidence interval, overall and stratified by 5-year age group, sex, occupation, education level, refractive status and screen exposure level. | ClinicalTrials.gov |
| Secondary | Amplitude of accommodation by age group | Day 1 (At the single study visit (cross-sectional assessment)) | Amplitude of accommodation in diopters, measured by the push-up method under full distance correction, repeated three times per eye and averaged. Reported as mean and standard deviation or median and interquartile range by 5-year age group, and used to fit the accommodation-age curve. | ClinicalTrials.gov |
| Secondary | Adjusted odds ratios for factors associated with presbyopia | Day 1 (At the single study visit (cross-sectional assessment)) | Association of presbyopia with age, sex, education level, occupation and job type, refractive status, near-work duration, screen exposure, sleep duration and quality, outdoor activity and dry eye measures, estimated by generalized estimating equations or mixed-effects logistic regression with workplace as a clustering variable or random effect. Reported as adjusted odds ratios with 95 percent confidence intervals. | ClinicalTrials.gov |
| Secondary | Awareness of presbyopia and need for near vision correction | Day 1 (At the single study visit (cross-sectional assessment)) | Description: Questionnaire-based assessment of awareness and understanding of presbyopia, previous care-seeking, current correction methods and wearing time, acceptance of correction options, acceptable price range, and future intention to use correction. Near vision-related quality of life assessed with the Chinese version of the Near Activity Visual Questionnaire for Presbyopia (NAVQ-P). Reported as frequencies and percentages. | ClinicalTrials.gov |
| Secondary | Correlation between presbyopia severity grade and dry eye severity grade | Day 1 (At the single study visit (cross-sectional assessment)) | Dry eye graded as mild, moderate or severe based on the Ocular Surface Disease Index (OSDI), non-invasive tear break-up time, tear meniscus height and slit-lamp findings. Correlation with presbyopia severity grade assessed by Spearman rank correlation and, where appropriate, ordinal logistic regression adjusted for age, sex, refractive status, screen exposure and near-work load. | ClinicalTrials.gov |
| Secondary | Agreement between NVC mini-program outputs and subjective refraction | Day 1 (At the single study visit (cross-sectional assessment)) | The near-fatigue severity grade and recommended ADD range output by the NVC mini-program will be compared with the reference ADD obtained by subjective refraction. Agreement measures include overall percent agreement, the proportion of classifications differing by one grade, the proportion differing by two or more grades, and Kendall's tau-b correlation between NVC grades and clinical grades. The proportion of reference ADD values falling within the NVC-recommended ranges will also be calculated. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)